Ashish M. Kamat, MD, MBBS (@UroDocAsh) ranks #13 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 35 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: IMvigor011, POTOMAC. CMS Open Payments lists $122,152 in 2025 general payments.
At a Glance
- 5 posts naming a trial in 2026
- 2 trials discussed by name
- GU Cancer: US #13, Global #20 · 35 physicians engaged
- CMS Open Payments lists $122,152 in 2025 general payments.
This Month
What Ashish M. Kamat, MD, MBBS has posted in the last 30 days. Updated November 10, 2026.
So where are we now? • Early RC remains the default for cT1 MP in a fit patient. • Bladder sparing is now a reasonable conversation for a narrow group: focal MP on expert GU pathology review, no LVI, no CIS, a clean re-TURBT What could move this further? • BCG plus checkpoint inhibition (CREST, POTOMAC, ALBAN enrolled few variant patients, so the answer is unknown). @eugene_pietzak • HER2, amplified far more often in MP than in conventional UC. @niklas_kluemper • And biomarkers such as ctDNA that might tell us which “T1” patients are already understaged.
Who Amplifies Ashish M. Kamat, MD, MBBS
Physicians who reposted Ashish M. Kamat, MD, MBBS’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #13 | #20 | 35 | 44 | Full ranking |
What Colleagues Are Saying About Ashish M. Kamat, MD, MBBS
2026 posts by fellow physicians that mention @UroDocAsh, quoted word for word.
Countdown to #AACR26 begins! Come join us at this session to learn about the exciting changes in #bladdercancer research and clinical care. Speakers: @FaltasLab @WeillCornell @MattGalsky, @MountSinaiNYC @UroDocAsh, @UTMDAnderson https://t.co/HVqSh2jr9z
Trials Ashish M. Kamat, MD, MBBS Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| IMvigor011 | 3 | #12 of 20 | Aug 6, 2026 |
| POTOMAC | 2 | #4 of 17 | Oct 22, 2026 |
Ashish M. Kamat, MD, MBBS on IMvigor011
4/MIBC: is where the ground is actually moving! ctDNA post-RC is prognostic and, per IMvigor 011, predictive - level 1 evidence that in specific context of chemotherapy, ctDNA-positive patients benefit from adjuvant atezo while ctDNA-negative can be spared unnecessary treatment. @tompowles1 What ctDNA still cannot do: tell you whether to skip cystectomy after a good response to systemic therapy. Local consolidation stays the standard until a trial proves otherwise.
Kudos to @tompowles1 and the IMvigor011 team for turning a 'negative trial' into a practice-changing paradigm. Negative trials are not failures. They provide data. This is how science is supposed to work. #AUA26 https://t.co/US6hY0VJBa
@DrChoueiri @FDA @NateraGenetics @tompowles1 @BladderCancerUS @ASCO @NEJM @OncoBellmunt @DrRosenbergMSK @bergsa83 Kudos to @tompowles1 and the IMvigor011 team for turning a 'negative trial' into a practice-changing paradigm @Uromigos
Ashish M. Kamat, MD, MBBS on POTOMAC
So where are we now? • Early RC remains the default for cT1 MP in a fit patient. • Bladder sparing is now a reasonable conversation for a narrow group: focal MP on expert GU pathology review, no LVI, no CIS, a clean re-TURBT What could move this further? • BCG plus checkpoint inhibition (CREST, POTOMAC, ALBAN enrolled few variant patients, so the answer is unknown). @eugene_pietzak • HER2, amplified far more often in MP than in conventional UC. @niklas_kluemper • And biomarkers such as ctDNA that might tell us which “T1” patients are already understaged.
People have been DM and asking me: with an HR of 0.68 for durvalumab + BCG in POTOMAC, why isn’t this for every high-risk NMIBC patient? Here’s how hazard ratios work – and why they can mislead you if you stop there. 🧵 #ASCO26 @tompowles1 @WesKassouf @shilpaonc @DrFelixGuerrero
Ashish M. Kamat, MD, MBBS’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
FDA approves durvalumab in combination with BCG for high-risk non-muscle invasive #bladdercancer @IBCG_BladderCA @DrFelixGuerrero @joanfundi @tompowles1 @AndreaNecchi @JoshMeeks #ASCO26 https://t.co/UJasvdJCQq
Come join us at #AACR26 where we will discuss this and other advances across the full bladder cancer disease continuum 📅 April 19, 1–2:30 PM. #BladderCancer @AACR @UroToday @FaltasLab @MattGalsky https://t.co/o6HU3uSihr
Looking forward to joining @FaltasLab & @MattGalsky for this session at #AACR26 where we will discuss latest advances across the full bladder cancer disease continuum 📅 April 19, 1–2:30 PM. #BladderCancer @AACR @UroToday https://t.co/GC25cdYghV
Appreciate kind words Simon. If it sparks even a small shift in how we think about dose in BCG immunotherapy - and helps more patients access effective care in the middle of a seemingly never ending shortage - then the 'tweet' has done its job @BladderCancerUS @WorldBladderCan https://t.co/20MoTCYzIn
The approval answers one question, but leaves another unanswered: which patients truly derive enough benefit to justify escalation beyond optimized BCG? The FDA approval of durvalumab plus BCG in high-risk NMIBC was driven by a meaningful improvement in disease-free survival (HR 0.68), mainly recurrence free survival. Checkpoint inhibitors are not benign therapies, carrying ~ 15% risk of serious treatment-related adverse events. At the same time, this trial also demonstrated that patients with BCG-naïve high-risk NMIBC have low rates of progression and bladder cancer mortality, when treated with BCG appropriately. For many patients, the balance between reducing recurrence and exposing them to potentially significant toxicity is not straightforward. That raises a practical question: who should actually receive treatment intensification?
Industry Payments
CMS Open Payments · 2025 general payments
$122,152 across 45 payments